Literature DB >> 9708720

Nasal atropine sulfate: efficacy and safety of 0.050% and 0.075% solutions for severe rhinorrhea.

J W Georgitis1.   

Abstract

BACKGROUND: Anticholinergic agents, specifically the quaternary salt of atropine, are currently being recommended for chronic rhinitis and the common cold.
OBJECTIVE: To evaluate the efficacy and safety of 50- and 75-microg doses of atropine sulfate as a nasal spray in perennial allergic rhinitis.
METHODS: A placebo-controlled, double-blind study compared 2 doses of atropine nasal spray given 4 times daily for 2 weeks to 45 patients with perennial allergic rhinitis after a 2-week baseline period.
RESULTS: Both concentrations of atropine nasal spray improved the severity of rhinorrhea and postnasal drip (P<.001) as reported by patients and physicians. The duration of action in reducing rhinorrhea and postnasal drip for atropine was 2 to 3 hours, compared with less than 1 hour for placebo (P<.01). No difference was noted in efficacy between the 2 atropine doses nor in frequency of adverse events with atropine nasal spray and placebo.
CONCLUSIONS: Atropine sulfate, 50 or 75 microg 4 times daily, is effective in reducing rhinorrhea and postnasal drip within 2 weeks and may be an alternative therapy for the rhinorrhea component of rhinitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708720     DOI: 10.1001/archotol.124.8.916

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  3 in total

1.  Comparison of Intranasal Dexmedetomidine with Intranasal Clonidine as a Premedication in Surgery.

Authors:  Gurkaran Kaur Sidhu; Seema Jindal; Gurpreet Kaur; Gurpreet Singh; Kewal Krishan Gupta; Shobha Aggarwal
Journal:  Indian J Pediatr       Date:  2016-06-04       Impact factor: 1.967

2.  Anticholinergic drugs in nonallergic rhinitis.

Authors:  Robert Naclerio
Journal:  World Allergy Organ J       Date:  2009-08-15       Impact factor: 4.084

3.  Atropine toxicity caused by erroneous intranasal administration in a pediatric patient: case report.

Authors:  Lama S Alaula; Mohammad Al-Kadi; Abdullah Almajed; Riyadh Alhedaithy
Journal:  Ann Saudi Med       Date:  2019-08-05       Impact factor: 1.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.